PMID- 21083673
OWN - NLM
STAT- MEDLINE
DCOM- 20110314
LR  - 20220309
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 33
IP  - 2
DP  - 2011 Jan
TI  - Randomised clinical trial: high-dose acid suppression for chronic cough - a 
      double-blind, placebo-controlled study.
PG  - 225-34
LID - 10.1111/j.1365-2036.2010.04511.x [doi]
AB  - BACKGROUND: Cough may be a manifestation of gastro-oesophageal reflux disease 
      (GERD). The utility of acid suppression in GERD-related cough is uncertain. AIM: 
      To assess the impact of high-dose acid suppression with proton pump inhibitors 
      (PPI) on chronic cough in subjects with rare or no heartburn. METHODS: Subjects 
      were nonsmokers without history of asthma, with chronic cough for >8 weeks. All 
      subjects underwent a baseline 24-h pH/impedance study, methacholine challenge 
      test and laryngoscopy. Subjects were randomised to either 40 mg of esomeprazole 
      twice daily or placebo for 12 weeks. The primary outcome measure was the 
      Cough-Specific Quality of Life Questionnaire (CQLQ). Secondary outcomes were 
      response on Fisman Cough Severity/Frequency scores and change in laryngeal 
      findings. RESULTS: Forty subjects were randomised (22 PPI, 18 placebo) and 
      completed the study. There was no difference between PPI and placebo in CQLQ 
      (mean improvement 9.8 vs. 5.9 respectively, P = 0.3), or Fisman Cough 
      Severity/Frequency scores. Proportion of patients who improved by >1 s.d. on the 
      CQLQ was 27.8% (five of 18) and 31.8% (seven of 22) in the placebo and PPI groups 
      respectively. CONCLUSION: In subjects with chronic cough and rare or no 
      heartburn, high-dose proton pump inhibitor does not improve cough-related quality 
      of life or symptoms.
CI  - (c) 2010 Blackwell Publishing Ltd.
FAU - Shaheen, N J
AU  - Shaheen NJ
AD  - Center for Esophageal Diseases and Swallowing, University of North Carolina 
      School of Medicine, Chapel Hill, 27599-7080, USA. nshaheen@med.unc.edu
FAU - Crockett, S D
AU  - Crockett SD
FAU - Bright, S D
AU  - Bright SD
FAU - Madanick, R D
AU  - Madanick RD
FAU - Buckmire, R
AU  - Buckmire R
FAU - Couch, M
AU  - Couch M
FAU - Dellon, E S
AU  - Dellon ES
FAU - Galanko, J A
AU  - Galanko JA
FAU - Sharpless, G
AU  - Sharpless G
FAU - Morgan, D R
AU  - Morgan DR
FAU - Spacek, M B
AU  - Spacek MB
FAU - Heidt-Davis, P
AU  - Heidt-Davis P
FAU - Henke, D
AU  - Henke D
LA  - eng
GR  - T32 DK007634/DK/NIDDK NIH HHS/United States
GR  - T32 DK007634-22/DK/NIDDK NIH HHS/United States
GR  - P30 DK3497/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20101117
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Proton Pump Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Chronic Disease
MH  - Cough/complications/*drug therapy
MH  - Double-Blind Method
MH  - Esomeprazole/*therapeutic use
MH  - Female
MH  - Gastroesophageal Reflux/*complications/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Severity of Illness Index
MH  - Statistics as Topic
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC3073617
MID - NIHMS280491
COIS- Statement of interests: 1. Authors' declaration of personal interests: i. Dr. 
      Shaheen has served as a consultant to Astra Zeneca and CSA Medical, and has 
      received research support from Astra Zeneca, Takeda, Procter & Gamble, BARRX 
      Medical, CSA Medical and Oncoscope. ii. Dr. Madanick is on the speakers bureau 
      and has received honoraria from Astra Zeneca iii. Dr. Dellon has received 
      research support from Astra Zeneca. iv. Dr. Morgan has received research support 
      from Astra Zeneca. v. Dr. Henke is on the speakers bureau for Astra Zeneca. vi. 
      Other co-authors have no competing interests to declare 2. Declaration of funding 
      interests: i. This research was conducted with support from the 
      Investigator-Sponsored Study Program of AstraZeneca, LLP. ii. This research was 
      also supported, in part, by funding from the National Institutes of Health for 
      the Digestive Disease Epidemiology Training Program (T32 DK007634), and the 
      Center for Gastrointestinal Biology and Disease (P30 DK3497). iii. The study 
      sponsor had no role in the study design or the collection, analysis, or 
      interpretation of data.
EDAT- 2010/11/19 06:00
MHDA- 2011/03/15 06:00
PMCR- 2012/01/01
CRDT- 2010/11/19 06:00
PHST- 2010/11/19 06:00 [entrez]
PHST- 2010/11/19 06:00 [pubmed]
PHST- 2011/03/15 06:00 [medline]
PHST- 2012/01/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2036.2010.04511.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2011 Jan;33(2):225-34. doi: 
      10.1111/j.1365-2036.2010.04511.x. Epub 2010 Nov 17.